Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis by Gourh, Pravitt et al.
Extended report
Ann Rheum Dis 2010;69:550–555. doi:10.1136/ard.2009.116434 550
ABSTRACT
Objective  It is increasingly being appreciated 
that multiple autoimmune diseases share common 
susceptibility genes. The tumour necrosis factor ligand 
superfamily member 4 gene (TNFSF4, OX40L), which 
encodes for the T cell costimulatory molecule OX40 
ligand, has been identiﬁ  ed as a susceptibility gene for 
the development of systemic lupus erythematosus 
(SLE). Accordingly, the aim of the current study was to 
investigate the possible association of the TNFSF4 gene 
region with systemic sclerosis (SSc), an autoimmune 
disease that leads to the development of cutaneous and 
visceral ﬁ  brosis.
Methods  A total of 9 single nucleotide polymorphisms 
(SNPs) in the TNFSF4 gene region, previously associated 
with susceptibility to SLE, were tested for association 
with SSc in a collection of 1059 patients with SSc and 
698 controls.
Results  Case-control comparisons revealed a 
signiﬁ  cant association between susceptibility to 
SSc and the minor alleles at SNPs rs1234314 (OR 
1.20, 95% CI 1.04 to 1.4, pFDR=0.019), rs2205960 
(OR 1.24, 95% CI 1.10 to 1.50, pFDR=0.019) and 
rs844648 (OR 1.16, 95% CI 1.01 to 1.30, pFDR=0.032). 
The minor allele at rs844644 was protective (OR 
0.84, 95% CI 0.70 to 0.97, pFDR=0.038). Analysis of 
subsets of patients with SSc demonstrated signiﬁ  cant 
associations of the TNFSF4 SNPs with limited and 
diffuse SSc as well as speciﬁ  c SNPs that were 
associated with SSc-associated autoantibodies. Finally, 
the analyses suggest a potential interaction between 
two TNFSF4 SNPs, rs2205960 and rs844648, with 
regards to SSc susceptibility.
Conclusions  Polymorphisms in the TNFSF4 gene 
region are associated with susceptibility to SSc and 
its clinical and autoantibody subsets. TNFSF4 may be 
another gene that confers risk to multiple autoimmune 
diseases.
INTRODUCTION
Recently, a number of reports have identiﬁ  ed genes 
that are associated with the development of mul-
tiple autoimmune diseases suggesting that auto-
immune diseases share genetic risk factors.1–3 For 
example,  PTPN22 has been associated with the 
development of type I diabetes mellitus (TIDM), 
rheumatoid arthritis (RA) and systemic lupus ery-
thematosus (SLE).4–6 STAT4 is a susceptibility gene 
for the development of SLE and RA.7 8 Together 
these studies implicate dysregulation of common 
immune pathways due to polymorphisms in sev-
eral genes in the development of a variety of auto-
immune diseases.
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The tumour necrosis factor ligand superfam-
ily member 4 gene (TNFSF4,  OX40L), which 
encodes for the costimulatory molecule OX40 
ligand, has been identiﬁ  ed as a susceptibility gene 
for SLE in multiple studies.9–11 To date, polymor-
phisms in TNFSF4 also have been associated with 
atherosclerosis,12–14 but there are no published 
reports of the association of TNFSF4 with auto-
immune diseases such as RA, TIDM, or systemic 
sclerosis (scleroderma, SSc).
SSc is a chronic multisystem disease clinically 
characterised by progressive ﬁ  brosis in the skin 
and internal organs.15 Pathologically, SSc exhibits 
three cardinal features: inﬂ   ammation and auto-
immunity, vasculopathy and excessive extracel-
lular matrix deposition.15 The immune alterations 
that lead to the development of SSc are unknown, 
but multiple lines of evidence suggest that SSc 
may share common immune alterations with SLE. 
For example, similar to SLE, patients with SSc 
have a myriad of circulating antinuclear antibod-
ies.16 Furthermore, peripheral blood cells from a 
subset of patients with SLE and SSc have a pat-
tern of upregulation of type I interferon associated 
gene transcripts.17–19 These data now have been 
extended at the genetic level where SLE and SSc 
have been associated with polymorphisms in the 
interferon regulatory factor 5 (IRF5) gene, STAT4, 
PTPN22 and FAS.6–8 20–25
Given the association of polymorphisms in the 
TNFSF4 gene region with susceptibility to SLE as 
well as the potential common alterations in immune 
function and related genes between SLE and SSc, 
the current study sought to determine if polymor-
phisms in the TNFSF4 gene region are associated 
with SSc susceptibility in a large case-control study 
of North American Caucasian patients with SSc 
and healthy controls.
METHODS
Patients with SSc and controls
A total of 1059 Caucasian patients with SSc and 698 
healthy Caucasian controls from the Scleroderma 
Family Registry and DNA Repository26 and the 
University of Texas Rheumatology Division,27 dat-
ing from 1986 to present, including the Genetics 
versus Environment in Scleroderma Outcomes 
Study (GENISOS)16 formed the current cohort. 
All patients with SSc fulﬁ  lled American College 
of Rheumatology (ACR) preliminary criteria for 
disease classiﬁ  cation28 or had at least three of the 
ﬁ  ve CREST (for ‘Calcinosis, Raynaud’s phenome-
non, Eesophageal dysfunction, Sclerodactyly and 
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Telangiectasias’) features.29 30 Patients were not excluded if 
they had symptoms of myositis or Sjogren’s syndrome. Patients 
in the registry were excluded if they met ACR criteria for SLE. 
In the division samples, one patient was subsequently diag-
nosed as having SLE. The patients were classiﬁ  ed as limited 
or diffuse cutaneous SSc according to published criteria.31 All 
participants provided written informed consent and the study 
was approved by the Committee for the Protection of Human 
Subjects of The University of Texas Health Science Centre at 
Houston.
Autoantibody analysis
Testing for antinuclear antibodies was performed using indirect 
immunoﬂ  uorescence (IIF) and HEp-2 cells as antigen substrate 
(Antibodies Inc, Davis, California, USA). Anti-centromere anti-
bodies (ACA) were determined by their distinctive IIF pattern 
on HEp-2 cells.32 Autoantibodies to topoisomerase I (ATA) were 
determined by passive immunodiffusion (Inova Diagnostics, 
San Diego, California, USA). Anti-RNA polymerase III antibod-
ies (ARA) were determined by enzyme-linked immunoassay 
(MBL, Nagoya, Japan).
SNP selection and genotyping
Single nucleotide polymorphisms (SNPs) in the TNFSF4 gene 
region were selected based on TNFSF4 variants identiﬁ  ed in 
two independent candidate gene studies in SLE.9 11 Genomic 
DNA was extracted from peripheral blood with the PureGene 
genomic DNA isolation kit (Gentra Systems, Minneapolis, 
Minnesota, USA). The following TNFSF4 SNPs were geno-
typed: rs1234314, rs1234315, rs2205960, rs844644, rs12039904, 
rs2795288, rs844648, rs844665 and rs10912580, using an ABI 
TaqMan SNP genotyping assay from Applied Biosystems (Foster 
City, California, USA). ABI 7900HT real-time thermocycler was 
used to perform the plate reading. Automated allele calling was 
performed by allelic discrimination plots using SDS V.2.3 soft-
ware (Applied Biosystems). Multiple positive (Centre d’Etude 
du Polymorphisme Humain (CEPH) samples) and negative con-
trols were used in each genotyping assay and allele calls were 
veriﬁ  ed with HapMap data for validation.
Statistical analysis
Statistical analyses were performed using SAS V.9.1.3 (SAS 
Institute Inc, Cary, North Carolina, USA) software. Hardy–
Weinberg equilibrium (HWE) testing was performed using the 
exact test for HWE. Allelic and genotypic associations were 
calculated using the standard Pearson χ2 test or Fisher exact 
test. Statistical signiﬁcance was considered at p<0.05 after cor-
recting for multiple comparisons using a false discovery rate 
method (pFDR).33 Logistic regression analysis was performed 
to conﬁ   rm these associations. Measures of pairwise link-
age disequilibrium (LD) were determined using Haploview 
(Whitehead Institute for Biomedical Research, Cambridge, 
Massachusetts, USA). SAS was used for overall (‘omnibus 
test’) haplotype frequency tests as well as for haplotype-spe-
ciﬁ  c tests. The ‘omnibus test’ was evaluated to detect differ-
ences in overall haplotype frequency proﬁ  les between SSc and 
controls. Classiﬁ  cation and regression tree (CART) analysis 
was performed to explore interactions between SNPs (CART 
V.6.0; Salford Systems, San Diego, California, USA) using gen-
der and SNPs of TNFSF4 as nominal categorical variables to 
predict the outcome of SSc.34 Logistic regression analysis was 
performed to verify the SNP interaction observed in CART 
analysis.
RESULTS
Linkage disequilibrium in the TNFSF4 gene region in healthy 
controls
A candidate gene association study was conducted using 1059 
Caucasian patients with SSc and 698 healthy controls. Clinical and 
serological data for the patients with SSc are presented in table 1. 
Nine TNFSF4 SNPs previously associated with susceptibility to 
SLE were genotyped in patients with SSc and controls. All SNPs 
studied in the TNFSF4 gene region were in HWE in Caucasian con-
trols (see supplementary material). Pairwise LD was calculated by 
D′ and r2 for TNFSF4 SNPs typed in Caucasian controls (ﬁ  gure 1). 
Table 1  Clinical and serological characteristics of 
patients with systemic sclerosis
Characteristic Value
Controls:
Gender (N=698)*
 Female 334  (50.8)
 Male 323  (49.2)
Systemic sclerosis:
Gender (N=1059)
 Female 935  (88.3)
 Male 124  (11.7)
Skin involvement (N=1004)
  Limited systemic sclerosis 611 (60.9)
  Diffuse systemic sclerosis 393 (39.1)
SSc-associated autoantibodies (N=1059)
 Anti-centromere 300  (28.3)
  Anti-topoisomerase I 174 (16.4)
  Anti-RNA polymerase III 193 (18.2)
    Neither anti-centromere, anti-topoisomerase I, 
or anti-RNA polymerase III
392 (37.1)
Values are number (%). 
*Missing gender information on 41 controls.
Figure 1  Linkage disequilibrium (LD) and haplotype block structure of 
the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) 
within healthy controls. Blocks connecting pairs of single nucleotide 
polymorphisms (SNPs) are shaded according to the strength of the linkage 
disequilibrium between the SNPs, from 0.0 (white) to 1.0 (black), as 
measured by the disequilibrium coefﬁ  cient D’. As an additional measure of 
strength of LD, r2 values are given as numerical values within each box.
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The TNFSF4 SNPs rs1234314–rs1234315, rs2205960–rs12039904, 
rs2205960–rs10912580, rs12039904–rs10912580 and rs2795288–
rs844648 showed LD in the Caucasian population (r2 ≥0.80). Given 
the tight LD of these SNPs, rs1234315, rs12039904, rs10912580 
and rs2795288 were not used in subsequent analyses and the 
case-control comparisons were performed on the remaining ﬁ  ve 
SNPs tagging the TNFSF4 region.
TNFSF4 polymorphisms and association with SSc
Case-control comparisons for genotypes using the χ2 test dem-
onstrated signiﬁ  cant association for multiple SNPs in the TNFSF4 
gene region (table 2). These associations remained signiﬁ  cant 
even after controlling for multiple comparisons using the false 
discovery rate method. Compared to controls, patients with SSc 
had a higher frequency of the minor allele at rs1234314 (OR 1.2, 
95% CI 1.04 to 1.4), rs2205960 (OR 1.2, 95% CI 1.1 to 1.5) and 
rs844648 (OR 1.2, 95% CI 1.01 to 1.3). The minor allele fre-
quency at rs844648 was less common in patients with SSc com-
pared to controls (OR 0.8, 95% CI 0.7 to 0.97). These data were 
conﬁ  rmed using logistic regression analyses after controlling for 
gender (ﬁ  gure 2). No signiﬁ  cant difference was observed between 
patients with SSc and controls for the rs844665 variant.
Analysis of the 5-SNP marker set (rs1234314, rs2205960, 
rs844644, rs844648, rs844665) in the TNFSF4 revealed 5 out 
of 28 speciﬁ  c 5-marker haplotypes that were associated with 
SSc (table 3). Four risk haplotypes were identiﬁ  ed: C-G-A-A-C 
(p<10−4),  G-G-C-G-C (p=0.0006), G-G-C-G-T  (p<10−4) and 
G-T-C-G-C (p<10−4). Consistent with the individual SNP 3×2 
χ2 analysis, the C-G-A-G-C was found to be protective for the 
development of SSc (p<10−4). These data support the genetic 
associations of SNPs in TNFSF4 with SSc susceptibility observed 
in the case-control comparisons in table 2.
TNFSF4 polymorphisms and association with subsets of SSc
SSc is a clinically heterogeneous disease that is divided into two 
main clinical subsets based on the extent of cutaneous involve-
ment: limited (lSSc) and diffuse (dSSc).31 Furthermore, the pres-
ence of SSc-associated autoantibodies such as ACA, ATA and 
ARA is associated with distinct clinical subsets characterised by 
extent of cutaneous involvement and pattern of organ involve-
ment.35 Several studies have recently shown that certain genetic 
polymorphisms may have stronger associations with particular 
phenotypic subsets.21 36 Therefore, we compared the frequency 
of TNFSF4 SNPs within the clinical and autoantibody subsets of 
patients with SSc (table 4).
The minor alleles at TNFSF4 SNPs rs1234314 and rs2205960 
were more common in lSSc compared to controls. No differ-
ences were observed with rs844644 and rs844648 between lSSc 
and controls. Compared to controls, the patients with dSSc had 
an increased frequency of the minor alleles at TNFSF4 SNPs 
rs1234314, rs2205960 and rs844648 and decreased frequency 
of the minor allele at rs844644. Comparison of patients with 
and without pulmonary ﬁ  brosis or pulmonary hypertension did 
not reveal any differences in the frequency of the SNPs in the 
TNFSF4 gene region.
Using the SSc-associated autoantibodies to subset patients 
with SSc, a signiﬁ  cant association was observed with rs1234214 
and ACA-positive (OR 1.3, 95% CI 1.1 to 1.6) and ATA-positive 
patients with SSc (OR 1.3, 95% CI 1.02 to 1.7) compared to con-
trols. The minor allele at rs2205960 was more frequent in ATA-
positive SSc compared to controls (OR 1.4, 95% CI 1.1 to 1.9). 
Interestingly, only rs844648 was noted to be associated with 
ARA-positive SSc compared to controls (OR 1.4, 95% CI 1.1 to 
1.8). No signiﬁ  cant differences were noted in the SSc-associated 
autoantibody subsets of SSc compared to controls at rs844644.
Additional analyses were performed using logistic regression 
with gender added to the model (ﬁ  gure 2). The strongest asso-
ciations were observed with rs2205960, where the minor allele 
was observed with increased frequency in lSSc and dSSc as well 
Table 2  Distribution of the tumour necrosis factor ligand superfamily 
member 4 gene (TNFSF4) SNP genotype in North American Caucasian 
patients with SSc and normal controls*
MAF (%) Allelic χ2 p value and OR
SNP 
(minor allele) Position (bp)
Controls 
(N=698)
SSc 
(N=1059) pU pFDR OR (95% CI)
rs1234314 (G) 171444015 41.3 45.8 0.01 0.019 1.20 (1.04 to 1.4)
rs2205960 (T) 171458098 21.2 25.0 0.01 0.019 1.24 (1.1 to 1.5)
rs844644 (A) 171476118 49.1 44.7 0.01 0.019 0.84 (0.7 to 0.97)
rs844648 (A) 171490486 41.4 45.2 0.03 0.038 1.16 (1.01 to 1.3)
rs844665 (T) 171515580 7.3 8.3 0.31 0.31 1.19 (0.9 to 1.5)
*Controls are used as reference for all comparisons. 
bp, base pairs; MAF, minor allele frequency; pFDR, corrected p values using Benjamini 
and Hochberg false discovery rate method; pU, uncorrected χ2 p values; SSc, systemic 
sclerosis; SNP, single nucleotide polymorphism.
Figure 2  Estimated risk of the tumour necrosis factor ligand 
superfamily member 4 gene (TNFSF4) single nucleotide polymorphisms 
(SNPs) in systemic sclerosis (SSc) and subsets of SSc compared to 
controls by logistic regression controlling for gender.
Table 3  Haplotype analysis of the 5-SNP marker set in the tumour 
necrosis factor ligand superfamily member 4 gene (TNFSF4) in 
Caucasian patients with SSc and controls
Haplotype* Controls (N=694) SSc (N=1050) χ2 pU Effect direction
OMNIBUS NA NA 164.3 <0.0001
C-G-A-A-C 0.6% 4.9% 52.6 <0.0001 Risk
C-G-A-G-C 43.4% 35.1% 25.3 <0.0001 Protective
G-G-C-G-C 0.4% 1.7% 12.1 0.0006 Risk
G-G-C-G-T 0.0% 1.4% 20.6 <0.0001 Risk
G-T-C-G-C 0.6% 3.9% 37.6 <0.0001 Risk
Others† 55.0% 53.0%     Neutral
*The order of the SNPs is rs1234314–rs2205960–rs844644–rs844648–rs844665.
†Includes 23 other haplotypes.
NA, not applicable; pU, uncorrected χ2 p values; SSc, systemic sclerosis; SNP, single 
nucleotide polymorphism.
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CART analysis for SNP interaction in the TNFSF4 gene region
To identify the SNP(s) in TNFSF4 that play a more prominent 
role in SSc susceptibility, CART analysis was performed.37 
Accordingly, the ﬁ  ve TNFSF4 polymorphisms and gender were 
entered as variables in the CART model. CART analysis interac-
tively segregates participants into two subgroups using the most 
powerful variable classiﬁ  er for SSc.
Figure 3 depicts female gender as the ﬁ  rst split. In women, 
the ‘TT/GT’ genotype of the TNFSF4 variant (rs2205960) 
increased risk for SSc as compared to the ‘GG’ wild-type 
Table 4  Distribution of the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) SNP alleles in North American Caucasian patients 
with SSc and normal controls*
Allelic comparison
%
NC Gp U pFDR OR (95% CI)
rs1234314
 Controls 1362 58.7 41.3
  Patients with systemic sclerosis 2086 54.2 45.8 0.01 0.019 1.20 (1.04 to 1.4)
  Limited systemic sclerosis 1202 53.4 46.6 0.009 0.026 1.24 (1.1 to 1.5)
  Diffuse systemic sclerosis 774 54.3 45.7 0.048 0.048 1.20 (1.1 to 1.4)
 Antibodies
  Anti-centromere 586 51.7 48.3 0.005 0.018 1.33 (1.1 to 1.6)
  Anti-topoisomerase I 344 52.0 48.0 0.026 0.052 1.31 (1.02 to 1.7)
  Anti-RNA polymerase III 380 54.7 45.3 0.17 0.23 1.17 (0.9 to 1.5)
rs2205960
 Controls 1378 78.8 21.2
  Patients with systemic sclerosis 2058 75.0 25.0 0.01 0.019 1.24(1.1 to 1.5)
  Limited systemic sclerosis 1184 74.7 25.3 0.013 0.026 1.26 (1.1 to 1.5)
  Diffuse systemic sclerosis 764 74.9 25.1 0.037 0.048 1.25 (1.01 to 1.6)
 Antibodies
  Anti-centromere 586 74.4 25.6 0.032 0.056 1.28 (1.01 to 1.6)
  Anti-topoisomerase I 342 72.5 27.5 0.012 0.048 1.41 (1.1 to 1.9)
  Anti-RNA polymerase III 372 74.2 25.8 0.057 0.11 1.29 (0.98 to 1.7)
rs844644
 Controls 1378 49.1 50.9
  Patients with systemic sclerosis 2090 44.8 55.2 0.01 0.019 0.84 (0.7 to 0.97)
  Limited systemic sclerosis 1206 45.1 54.9 0.045 0.06 0.85 (0.7 to 1.0)
  Diffuse systemic sclerosis 774 43.8 56.2 0.019 0.038 0.81 (0.7 to 0.97)
 Antibodies
  Anti-centromere 590 44.1 55.9 0.042 0.056 0.82 (0.7 to 1.0)
  Anti-topoisomerase I 346 43.1 56.9 0.046 0.055 0.79 (0.6 to 1.0)
  Anti-RNA polymerase III 380 45.8 54.2 0.26 0.26 0.88 (0.7 to 1.1)
rs844648
 Controls 1384 41.4 58.6
  Patients with systemic sclerosis 2094 45.1 54.9 0.03 0.032 1.16 (1.01 to 1.3)
  Limited systemic sclerosis 1206 44.0 56.0 0.18 0.18 1.11 (0.95 to 1.3)
  Diffuse systemic sclerosis 778 48.2 51.8 0.002 0.008 1.32 (1.1 to 1.6)
 Antibodies
  Anti-centromere 592 42.6 57.4 0.63 0.63 1.05 (0.9 to 1.3)
  Anti-topoisomerase I 346 47.1 52.9 0.055 0.055 1.26 (0.99 to 1.6)
  Anti-RNA polymerase III 382 49.7 50.3 0.004 0.014 1.40 (1.1 to 1.8)
*Controls are used as reference for all comparisons.
pFDR, corrected p values using Benjamini and Hochberg false discovery rate method; pU, raw χ2 p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.
as the autoantibody subsets. The minor allele at rs844644 was 
protective in all groups except for the patients who were ARA 
positive. With regards to rs1234314, the associations remained 
in lSSc, ACA and ATA groups. However, the association of 
rs1234314 was no longer observed after controlling for gender in 
the logistic regression analyses. Lastly, with regards to rs844648, 
logistic regression conﬁ   rmed the association with dSSc and 
ARA. Together these data suggest that different polymorphisms 
in the TNFSF4 gene region are associated with susceptibility to 
the distinct autoantibody and skin subsets in SSc.
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genotype (OR = 1.51, 95% CI 1.2 to 1.9) consistent with a dom-
inant model. The individuals with wild-type genotype ‘GG’ at 
rs2205960 were subsequently further split by the TNFSF4 var-
iant (rs855648) into two subgroups: the ‘AA’ genotype of the 
TNFSF4 variant increased risk for SSc as compared to the ‘AG/
GG’ genotypes (OR=2.55, 95% CI 1.3 to 5.3). Therefore, this 
analysis uncovered a potential interaction between the rs2205960 
and rs855648 SNPs in the TNFSF4 gene region among women 
patients with SSc. This interaction between the two TNFSF4 
variants, rs2205960 and rs855648, was further tested and con-
ﬁ  rmed by an interaction model in logistic regression analysis 
(p=0.0004).
DISCUSSION
The current report is the ﬁ  rst demonstration of an association 
of polymorphisms in the TNFSF4 gene region with suscep-
tibility to SSc in North American Caucasians. These asso-
ciations were similar when comparing lSSc and dSSc with 
controls. We also identiﬁ  ed particular SNPs in the TNFSF4 
gene region that are associated with the SSc-associated auto-
antibody subsets of SSc. Lastly, the exploratory method 
of analysis, CART, demonstrated a potential interaction 
between the TNFSF4 SNPs rs2205960 and rs855648 among 
Caucasian women patients with SSc that was conﬁ  rmed by 
logistic regression analysis.
TNFSF4 encodes for the protein OX40 ligand (OX40L). 
OX40L is expressed on dendritic cells, macrophages, B cells, 
T cells, natural killer (NK) cells as well as non-immune cells 
such as endothelial cells and smooth muscle cells.38 It is the 
ligand for the OX40 which is expressed on CD4+ and CD8+ 
T cells, where it provides a costimulatory signal resulting in 
T cell proliferation, survival and cytokine production.38 Several 
studies have suggested that OX40–OX40L interaction may 
preferentially promote T helper (Th)2 cytokines and may be a 
negative regulatory signal for interleukin (IL)17 production.39–41 
More recently it has been suggested that OX40–OX40L inter-
actions inhibit the formation of Foxp3+ regulatory T cells.42 
In addition to T cell effects, OX40–OX40L interactions also 
have been reported to be critical in differentiation of B cells 
and antibody production.43–45 Lastly, it has been reported that 
plasmacytoid dendritic cells may regulate T helper responses 
through a balance of OX40L expression and type I interferon 
expression such that OX40L alone induces a Th2 response 
and OX40L with type I interferon may have a Th1 inducing 
effect.46 Together these studies suggest an important role for 
OX40–OX40L interactions in critical immunoregulatory check-
points that are likely involved in the development of auto-
immunity. Accordingly, OX40L transgenic mice on the C57/BL6 
background develop organ speciﬁ  c inﬂ  ammation and   targeted 
strategies to block OX40–OX40L interactions have prevented 
the development of diabetes in the non-obese diabetic mouse 
and experimental autoimmune encephalomyelitis, a model 
for multiple sclerosis.47–49 It is likely that these pathways and 
OX40L-dependent immune alterations are important in the 
development of SSc. Indeed serum levels of OX40 have been 
reported to be elevated in patients with SSc, suggesting that the 
OX40–OX40L pathway may be involved in SSc.50 However, 
speciﬁ  cally how the OX40L polymorphisms lead to the devel-
opment of SSc is unknown.
The current report adds TNFSF4 to the list of genes that are 
associated with SSc susceptibility which includes major his-
tocompatibility complex (MHC) class II, PTPN22, AIF1, IRF5, 
STAT4 and FAS.8 21–23 36 51 Furthermore, given the association 
of TNFSF4 with SLE as well as SSc, it is likely that TNFSF4 is 
a gene that confers risk to multiple autoimmune diseases. Why 
individual patients will develop a speciﬁ  c autoimmune disease 
such as SLE, RA, or SSc remains unknown. Functional studies 
of the polymorphisms in these genes as well as studies of gene–
gene and gene–environment interactions are necessary to better 
understand how the genetic associations lead to speciﬁ  c auto-
immune diseases.
Our study, despite its large size, is limited to the North 
American Caucasian population. Current efforts are underway 
to conﬁ  rm these ﬁ  ndings in other populations. However, we 
believe that the prior association of TNFSF4 with SLE and the 
emerging concepts of shared autoimmune genes provide some 
validation of our novel ﬁ  ndings in SSc. Furthermore, the odds 
ratios that we observed in the current study are small, but sta-
tistically signiﬁ  cant. It is well established that SSc and other 
autoimmune diseases are complex polygenic diseases and it 
will be important to investigate for interactions among these 
candidate genes in the future. Another important limitation to 
consider when interpreting the ﬁ  ndings of the current study is 
that our data demonstrate an association of a region 5′ of the 
TNFSF4 gene region with SSc susceptibility. These SNPs have 
been reported to be within the promoter region of TNFSF4 but 
their speciﬁ  c regulatory role is not known.11 Higher resolution 
genotyping or DNA sequencing of this region gene will help to 
identify the SNPs involved in SSc pathogenesis and also deter-
mine the variation in genetic structure of this gene in various 
populations.
To summarise, the current report identiﬁ  es TNFSF4 as a sus-
ceptibility gene for the development of SSc. These data further 
our understanding of the complex immunopathogenesis of SSc 
and provide additional support for the emerging concept of 
shared genes in multiple autoimmune diseases.
Figure 3  Cartesian and regression tree analysis (CART) showing 
an interaction between the tumour necrosis factor ligand superfamily 
member 4 gene (TNFSF4) single nucleotide polymorphisms (SNPs) 
rs2205960 and rs944648 in systemic sclerosis (SSc). Red test result 
denotes SSc susceptibility factors.
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